The Effect of Serum Ferritin in irAE

Exclusion Criteria

• •Patient who meet any of the following conditions well excluded in this trial:
• •1. Active systemic autoimmune disease is known before screening and is under treatment;
• •2. Those who stopped systemic hormone therapy for less than 2 weeks before enrollment；
• •3. Those who have received organ / tissue transplantation before screening;
• •4. Those who meet any of the following conditions during screening:
• •* positive for hepatitis B surface antigen (HBsAg) and / or hepatitis B e antigen (HBeAg);
• •* hepatitis B e antibody (HBE AB) and / or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit;
• •* positive for hepatitis C antibody (HCV AB);
• •* positive anti Treponema pallidum antibody (TP AB);
• •* HIV antibody test positive;
• •* the copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit;
• •5. The heart meets any of the following conditions during screening:
• •* left ventricular ejection fraction (LVEF) ≤ 50% (echo);
• •* New York Heart Association (NYHA) class III or IV congestive heart failure;
• •* hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension that has not been controlled by standard treatment;
• •* have had myocardial infarction or cardiac surgery within 12 months before cell transfusion;
• •* clinically significant valvular disease.
• •6. There are clinical emergencies (such as intestinal obstruction or vascular compression) requiring urgent treatment due to tumor body obstruction or compression during screening;
• •7. Patients with active bleeding during screening;
• •8. Patients with deep venous thrombosis or pulmonary embolism within 6 months before screening;
• •9. Those who received live vaccine within 6 weeks before screening;
• •10. Patients with active infection and need treatment during screening;
• •11. Poor compliance.